Compare Guardant Health Inc. Common Stock (GH) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B). The key difference: Guardant Health Inc. Common Stock is far larger — about 16× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Americas Gold and Silver Corporation Common Shares no par value nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| GH | USAS | |
|---|---|---|
Market Cap | $21.74B | $1.36B |
Volume | 1,297,295 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $187.22 | $10.03 |
52-Week Low | $64.19 | $3.59 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $1.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
